

PRESS RELEASE

01 February 2023 08:59:00 CET

Senzime wins large order for its pediatric sensor in the US

One of the leading pediatric hospitals in the US will implement Senzime's quantitative neuromuscular monitoring system

Uppsala, February 1, 2023. Senzime AB (publ) today announced that one of the leading pediatric hospitals in the US has decided to buy the TetraGraph® system and the TetraSens® pediatric sensor to implement quantitative neuromuscular monitoring. The order is expected to generate annual sales greater than 2 million SEK when fully implemented. TetraGraph together with the flexible TetraSens Pediatric sensor enables accurate monitoring of infants and young children who are receiving muscle paralyzing drugs as part of anesthesia.

In the end of 2022, the American Society of Anesthesiologists (ASA) published clinical guidelines recommending Senzime's type of technology for neuromuscular monitoring. The guidelines are focused on adult patients and have created a growing momentum and general interest in quantitative neuromuscular monitoring. Today's order was the second from a hospital with a focus on pediatrics.

"Improving the health and safety of children is one of our priorities. I am proud that our dedicated pediatric sensor is now starting to be used in pediatric hospitals, enabling gold standard quantitative neuromuscular monitoring for this vulnerable patient group", said Pia Renaudin, CEO of Senzime.

Senzime's system for monitoring of neuromuscular blockade during and after surgery – TetraGraph – is FDA-cleared since 2019. TetraGraph for use in children with the TetraSens Pediatric sensor received FDA 510k-clearance in August 2022.

About TetraSens® Pediatric

TetraSens Pediatric is a disposable sensor that delivers electrical stimulation to the peripheral nerve and directly measures the evoked electromyographic (EMG) response of the muscle (compound muscle action potential, CMAP). The pediatric sensor is a dedicated sensor for infants and up.

About TetraGraph®

TetraGraph® is a quantitative neuromuscular monitor, based on the gold standard electromyography (EMG) technology which provides accurate and versatile monitoring of neuromuscular blockade. The product is designed to meet the needs of monitoring physiological data during surgery of patients receiving general anesthesia and muscle relaxation using muscle paralyzing drugs. TetraGraph stimulates the patient's peripheral nerve using the TetraSens disposable sensors and measures, analyzes, and displays muscle function in real time. Thanks to its small size and versatile features, TetraGraph can be used in any type of surgery, anywhere in the hospital environment, and can be connected to external monitors and electronic hospital records.

For further information, please contact:

Pia Renaudin, CEO of Senszime AB

Phone: +46 (0) 708 13 34 17, e-mail: pia.renaudin@senzime.com

Paula Treutiger, Head of Communication and IR

Phone: +46 (0) 733 66 65 99, e-mail: paula.treutiger@senzime.com

About Senszime

Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senszime's employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpirom® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world's leading markets. The company's shares are listed on Nasdaq Stockholm Main Market (SEZI). More information is available at [senzime.com](https://www.senzime.com).

This information is information that Senszime is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-02-01 08:59 CET.

Attachments

[Senzime wins large order for its pediatric sensor in the US](#)